Jan. 28, 2013 Stem cells from bone marrow or fat improve recovery after stroke in rats, finds a study published in BioMed Central's open access journal Stem Cell Research & Therapy. Treatment with stem cells improved the amount of brain and nerve repair and the ability of the animals to complete behavioural tasks. Stem cell therapy holds promise for patients but there are many questions which need to be answered, regarding treatment protocols and which cell types to use. This research attempts to address some of these questions. Rats were treated intravenously with stem cells or saline 30 minutes after a stroke. At 24 hours after stroke the stem cell treated rats showed a better functional recovery. By two weeks these animals had near normal scores in the tests. This improvement was seen even though the stem cells did not appear to migrate to the damaged area of brain. The treated rats also had higher levels of biomarkers implicated in brain repair including, the growth factor VEGF. A positive result was seen for both fat (adipose) and bone-marrow derived stem cells. Dr Exuperio Dez-Tejedor from La Paz University Hospital, explained, "Improved recovery was seen regardless of origin of the stem … Continue reading →

The latest in stem cell research suggests that stem cells given in the vital period immediately after a stroke (known colloquially as the "golden hour") could make major headway in recovery. A research team in Bolivia injected rats with stem cells thirty minutes after a stroke, and discovered that they had almost completely normal brain function restored within two weeks. The team says that this has serious potential in human trials. Their study was led by Dr. Exuperio Diez-Tejedor from La Paz University Hospital, and supports previous studies that point in a similar direction: stem cells can be useful in treating stroke patients because they aid the body's ability to repair tissue damage. The stem cells used in this study were multipotent stromal cells extracted from fat and bone marrow. These are the types of stem cells that people are talking about when they talk of "master cells," the kind that can differentiate into many different cell types. Researchers hope that they will ultimately replace cells that are lost through disease or injury. The Bolivian study was published in the open-access journal Stem Cell Research and Therapy. The controversy surrounding stem cells, at least in the United States, has been … Continue reading →

Seattle, Washington (PRWEB) January 29, 2013 Patients report success with stem cell treatment for diabetics. Traveling4Health&Retirement (THR) announces their choice of a stem cell surgeon sponsor in Buenos Aires, a popular South America destination location for overseas retirement and medical travel. We are pleased to promote Dr. Alejandro Mesples as our medical services sponsor in Buenos Aires, said Ilene Little, CEO of Traveling4Health&Retirement. Dr. Mesples has published several papers in medical journals on the results of his research and therapy and is widely known and accepted as the authority on stem cell based surgery for diabetes using the patients own stem cells. Recent results of his ongoing research were published 1/22/13 in the latest issue (Vol.3 No.1,2013) of the SCD medical journal, paper ID 1080044. The sponsor selection was based on patient-generated reviews, interviews with the company leadership, and the strong support for the potential of the therapy and associated research as expressed in letters received from professors at the University of Padua in Italy and a professor of Endocrinology at Johns Hopkins. When patients rave about their medical outcomes and a providers customer service, that gets our attention, said Ilene Little, We only promote doctors and accept destination sponsorships … Continue reading →

Regulated information january 29, 2013 TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid Leuven (BELGIUM), Madrid (SPAIN) - January 29, 2013 - TiGenix (Euronext Brussels: TIG), a leader in the field of cell therapy, announced today that further to the cGMP inspection by the Spanish health authorities it has successfully renewed its manufacturing authorization for stem cell products at its manufacturing facility in Madrid, Spain. "The GMP facility in Madrid performs a vital function within our organization by manufacturing high-quality, clinical grade allogeneic stem cell products to fuel our key clinical programs," said Wilfried Dalemans, CTO of TiGenix. "It is an important stepping stone before we can move to commercial manufacturing at our state-of-the-art, central GMP manufacturing site in Sittard-Geleen, the Netherlands. Our strong cell therapy manufacturing capabilities place us at the forefront of the cell therapy industry." For more information: Eduardo Bravo Claudia D`Augusta Chief Executive Officer Chief Financial Officer eduardo.bravo@tigenix.com claudia.daugusta@tigenix.com Hans Herklots hans.herklots@tigenix.com +32 16 39 79 73 About TiGenix TiGenix NV (Euronext Brussels: TIG)is a leading European cell therapy companywith a marketed product for cartilage repair, ChondroCelect, and a strongpipeline with clinical stage allogeneic adult stem cell programsfor the treatment ofautoimmune and … Continue reading →